This is the triple therapy that improves survival in metastatic prostate cancer

Androgen deprivation therapy has been the standard of care for

for decades -those with metastatic disease at the time of diagnosis-.

In the last five years, it was first shown that adding the chemotherapy drug docetaxel improves survival, and, subsequently, that combining the second-generation androgen biosynthesis inhibitor drug abiraterone with antiandrogen therapy prolongs life in these patients.

Finally, in a study published today in

It has been shown that

to

therapy improves the results in this type of tumor even more.

"The combination of

,

, and

metastatic castration-sensitive prostate cancer

improved

survival

with moderately increased toxicity, mainly hypertension. This triple therapy

of care for these patients," the authors conclude in the medical journal.

The results of the study, called PEACE-1, were presented in a plenary session during the last

.

Among the European consortium of authors participating in this trial is

, head of the Genitourinary Tumors, Central Nervous System and Sarcoma Group of the Vall d'Hebron Institute of Oncology (VHIO), which is part of the Vall d'Hebron Campus .

"This is the

to show that a

metastatic prostate cancer

. Their findings, combined with evidence from other studies, support the idea that

of treatment is more effective than the use of treatments that are used sequentially when the disease has become resistant", explains Professor Carles.

The different treatments that have been tested

, and have already shown efficacy in the management of castration-resistant prostate cancer, as well as metastatic hormone-sensitive cancer.

Yes

, the fact of

and not sequentially is

In fact, during the ESMO congress, urologist

, from Charité University in Berlin, Germany, who is not an author of the study, commented on the findings that "have the potential to be

, since they do not we have to wait for the approval of a new drug Clearly positive results are reassuring and should convince patients and physicians to

treatment of

with metastatic and high-risk locally advanced castration/hormone-sensitive prostate cancer

."

In search of the best combination

The study involved

who were divided into

to find the combination of new therapies that offered the best results.

"The combination that we have seen that has a better result is the one in which

together

It was possible to observe that the

disease progression

with this combination, going from an average of 2.05 years without progression to 4.46, and that the

emphasizes Carles, who is also head of section and head of the Vall d'Hebron Genitourinary, Central Nervous System, Sarcoma and Tumors of Unknown Origin Unit.

The first signatory of the trial,

a medical oncologist at the Gustave Roussy Institute and professor of Oncology at the University of Paris-Saclay, in Villejuif, France, told the European meeting that "for the first time, these men

while their median survival was less than three years before 2015.

that should improve patient access worldwide."

In this regard, Professor Carles explains that the figure of 60 months of survival that has been achieved with the triple combination is "very good if one takes into account that

becoming resistant to castration in

, they were given

in this situation, so it is possible that these figures would have been even higher if this had not been the case.

The oncologist also highlights how the benefit has been achieved with a manageable

and acceptable increase in

metastatic prostate cancer

, so it is not clear whether this triple therapy could benefit

, that is, those in whom metastatic lesions appear some time after the diagnosis of a first neoplasm.

High metastatic load

"At a minimum, patients with a high metastatic burden who are fit enough to be treated with docetaxel should be considered for this triple systemic therapy. Of note,

is

for metastatic prostate cancer

and is close to becoming a generic medicine throughout the world", adds the author of the VHIO.

One

raised by these findings is whether combining

such

therapy with radiation therapy to the primary tumor will provide

for these patients with metastatic prostate cancer, something that is expected to undergo further study. analysis,

of overall survival events and progression-free survival in the population of men presenting with low-volume metastatic spread are reached.

Conforms to The Trust Project criteria

Know more

• cancer